Have a personal or library account? Click to login
Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations Cover

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations

Radiology and Oncology
Volume 48 (2014): Issue 4 (December 2014)
By: Matjaz Zwitter,  Karmen Stanic,  Mirjana Rajer,  Izidor Kern,  Martina Vrankar,  Natalija Edelbaher and  Viljem Kovac  
Open Access
|Nov 2014

Authors

Matjaz Zwitter

Karmen Stanic

Mirjana Rajer

Izidor Kern

Martina Vrankar

Natalija Edelbaher

Viljem Kovac

vkovac@onko-i.si

DOI: https://doi.org/10.2478/raon-2014-0038 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 361 - 368
Submitted on: Aug 25, 2014
|
Accepted on: Sep 8, 2014
|
Published on: Nov 5, 2014
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Non-small cell lung cancer,
EGFR activating mutations,
gemcitabine,
cisplatin,
erlotinib,
intercalated therapy,
metabolic response
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2014 Matjaz Zwitter, Karmen Stanic, Mirjana Rajer, Izidor Kern, Martina Vrankar, Natalija Edelbaher, Viljem Kovac, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 48 (2014): Issue 4 (December 2014)Next article